Czechia· CZ-0286134
TRESIBA
A insulin degludec product containing insulin degludec, registered in Czechia by Novo Nordisk A/S, Bagsvaerd. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Insulin degludec is registered in 14 of 19 countries.
Countries holding a registration under ATC A10AE06 (insulin degludec), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Insulin degludec · ATC A10AE06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- INSULIN DEGLUDEC
- Manufacturer
- Novo Nordisk A/S, Bagsvaerd
- Country
- Czechia (CZ)
- ATC code
- A10AE06
- ATC class
- Insulin degludec
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
431 interactions on record for insulin degludec.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin degludec · interactions on record
431 records
- 15 severe
- 366 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin degludec in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTresibaOrifarm Oy
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- BelgiumRyzodeg 100 U/mlNovo Nordisk
- United KingdomTresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- SpainTRESIBA 100 UNIDADES/ML FLEXTOUCH SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenTresiba FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SwitzerlandTresiba FlexTouch 100 E/ml, InjektionslösungNovo Nordisk Pharma AG
- IcelandTresibaNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tresiba Flexpen, Tresiba Flextouch
- Norway · Tresiba, Tresiba Flexpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1176b84b-7d00-4e72-b619-34f0d95c71be GET /v1/drugs/1176b84b-7d00-4e72-b619-34f0d95c71be?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL PEP",
"source": "sukl",
"strength": "100U/ML",
"pack_size": "5X3ML II",
"substance": "INSULIN DEGLUDEC",
"cz_kod_sukl": "0286134",
"product_type": "BT",
"substance_codes": "18626",
"registration_state": "R",
"registration_number": "EU/1/12/807/017"
}See everything about insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.